An MRI/ultrasound fusion platform that will transform the management of prostate cancer

Focal Healthcare has developed an MRI/ultrasound fusion platform that will transform the management of prostate cancer by enabling targeted diagnosis and targeted “focal” therapy. The platform consists of two products: Fusion Bx and Fusion MR.

Fusion Bx is a prostate fusion biopsy device, designed to provide urologists and radiologists with the ability to perform targeted prostate biopsies. It uses software-based algorithms to fuse an MRI with live ultrasound and visualize the prostate and suspicious regions in 3D to provide navigation assistance to target lesions. Furthermore, Fusion Bx uses a counterbalanced semi-robotic arm to support and track the movements of the ultrasound probe. This improves targeting accuracy and reduces the need for additional assistance during the biopsy procedure.

Fusion MR is a prostate MRI diagnosis and contouring software suite for interpreting MRIs of the prostate. It provides the initial step in the targeted biopsy procedure by allowing suspicious regions in the prostate to be identified and contoured quickly. This information is then provided to Fusion Bx to be fused with the live ultrasound. Together, Fusion Bx and Fusion MR can help identify cancers sooner so that patients can be treated sooner.

To learn more, visit: www.focalhealthcare.com